Nicholas Lemming, MD
Family Medicine · Seymour, INNPI 1427033562
Payments from drug & device makers
Across 380 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$858
- Novo Nordisk$851
- GSK$772
- AstraZeneca$524
- Merck$463
- Novartis$339
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,94399%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 67 | $858 |
| Novo Nordisk | 63 | $851 |
| GSK | 55 | $772 |
| AstraZeneca | 19 | $524 |
| Merck | 36 | $463 |
| Novartis | 15 | $339 |
| Boehringer Ingelheim | 19 | $329 |
| AbbVie(2 entities) | 14 | $285 |
| Pfizer | 12 | $171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $151 |
| E.r. Squibb & Sons, L.L.C. | 9 | $146 |
| Boston Scientific | 1 | $135 |
| Johnson & Johnson | 12 | $133 |
| Amgen | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Abbott | 3 | $59 |
| Eisai Inc. | 3 | $57 |
| Sanofi Pasteur Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Antares Pharma, Inc. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$169
- FARXIGA$169
- WATCHMAN Access System$135
How this compares
$6,025 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 406 | $349,363 |
| MounjaroTirzepatide | 253 | $280,615 |
| JardianceEmpagliflozin | 286 | $260,214 |
| OzempicSemaglutide | 210 | $214,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 178 | $161,279 |
| FarxigaDapagliflozin Propanediol | 111 | $100,131 |
| TrulicityDulaglutide | 69 | $96,219 |
| RybelsusSemaglutide | 74 | $95,528 |
| XareltoRivaroxaban | 94 | $82,200 |
| MyrbetriqMirabegron | 60 | $43,389 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $37,755 |
| EntrestoSacubitril/Valsartan | 36 | $27,944 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $27,891 |
| LinzessLinaclotide | 22 | $27,402 |
| Spiriva HandihalerTiotropium Bromide | 35 | $23,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $858 | $376,834322 claims |
| PfizerEliquis | $171 | $349,363406 claims |
| Novo NordiskOzempic, Rybelsus | $851 | $310,400284 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $329 | $289,018326 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $772 | $174,516205 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $524 | $141,235190 claims |
| Johnson & JohnsonXarelto | $133 | $82,20094 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $43,38960 claims |
| MerckJanuvia, Belsomra | $463 | $31,90851 claims |
| NovartisEntresto | $339 | $27,94436 claims |
| AbbVieLinzess | $285 | $27,40222 claims |
| Eisai Inc.Dayvigo | $57 | $5,92813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Seymour
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.